Good progress in Clinical Study in Cervicitis 2005.02.04

 
(Hong Kong, 4 February 2005) - Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) today announced that its clinical trial to demonstrate the efficacy and safety of Recombinant Human Interferon α-2b gel, the Group's flagship product - Yallaferon® on treatment of cervicitis, is progressing well.

In November 2003, Leespharm announced the approval received from SFDA of the PRC for conducting a clinical study on cervicitis with Yallaferon®. In September 2004, this randomized, double-blind, multi-center study was initiated by 8 leading hospitals situated in three major cities of the PRC, namely Beijing, Shanghai and Guangzhou. At the end of January, the participated centers have completed more than 50% of the enrollment for this 320 patients study. Researchers at these centers are satisfied with the progress of the study and the patients' responses so far. It is expected that the progression will be particularly speed up after Chinese New Year holiday. The Company currently expects the trial to be completed by mid-year 2005…
 


© Lee's Pharmaceutical Holdings Limited     Terms of Use   |   Privacy Statement Designed by YSD